NASDAQ:FATE

Fate Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy FATE

*Your capital is at risk

$2.22

-0.350 (-13.62%)

At Close: Jun 03, 2026

Fate Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 69.18. In total, the insiders bought 34.41M and sold 16.73M FATE shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	69.18
● Buy	34.41M shares
● Sell	16.73M shares
71% Buy Activity Moderate Positive Correlation
Sell Signal Low Confidence Apr 20, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 69.18. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 29, 2025 Buy	Stock Option (Right to Buy) A-Award	Epstein Robert S Director	Director	55 000 Value: $72.6K
May 29, 2025 Buy	Stock Option (Right to Buy) A-Award	Abernethy Matt Director	Director	110 000 Value: $145.2K
May 29, 2025 Buy	Stock Option (Right to Buy) A-Award	Agarwal Shefali Director	Director	55 000 Value: $72.6K
May 29, 2025 Buy	Common Stock J-Other	Abernethy Matt Insider	Other	0 Value: $0
May 29, 2025 Buy	Common Stock J-Other	Abernethy Matt Insider	Other	0 Value: $0
May 29, 2025 Buy	Stock Option (Right to Buy) A-Award	Agarwal Shefali Director	Director	55 000 Value: $72.6K
May 29, 2025 Buy	Stock Option (Right to Buy) A-Award	Abernethy Matt Director	Director	110 000 Value: $145.2K
May 29, 2025 Buy	Stock Option (Right to Buy) A-Award	Epstein Robert S Director	Director	55 000 Value: $72.6K
May 29, 2025 Buy	Stock Option (Right to Buy) A-Award	Jooss Karin Director	Director	55 000 Value: $72.6K
May 29, 2025 Buy	Stock Option (Right to Buy) A-Award	Mendlein John Director	Director	55 000 Value: $72.6K
May 29, 2025 Buy	Stock Option (Right to Buy) A-Award	Rastetter William H Director	Director	55 000 Value: $72.6K
May 29, 2025 Buy	Stock Option (Right to Buy) A-Award	Mozaffarian Neelufar Director	Director	55 000 Value: $72.6K
May 29, 2025 Buy	Stock Option (Right to Buy) A-Award	Xu Yuan Director	Director	55 000 Value: $72.6K
May 29, 2025 Buy	Stock Option (Right to Buy) A-Award	Redmile Group, Llc	Director	55 000 Value: $72.6K
May 29, 2025 Buy	Stock Option (Right to Buy) A-Award	Lee Michael Stewart Director	Director	55 000 Value: $72.6K
Jan 16, 2025 Buy	Stock Option (Right to Buy) A-Award	Valamehr Bahram President And CEO	CEO / President	1 300 000 Value: $1.63M
Jan 16, 2025 Buy	Stock Option (Right to Buy) A-Award	Valamehr Bahram President And CEO	CEO / President	1 300 000 Value: $1.63M
Jan 15, 2025 Buy	Common Stock A-Award	Tahl Cindy See Remarks	Officer	70 000 Value: $92.4K
Jan 15, 2025 Buy	Stock Option (Right to Buy) A-Award	Tahl Cindy See Remarks	Officer	275 000 Value: $363.0K
Jan 15, 2025 Buy	Common Stock A-Award	Bressi Jerome Charles See Remarks	Officer	65 000 Value: $85.8K
Jan 15, 2025 Buy	Stock Option (Right to Buy) A-Award	Bressi Jerome Charles See Remarks	Officer	250 000 Value: $330.0K
Jan 15, 2025 Buy	Stock Option (Right to Buy) A-Award	Bressi Jerome Charles See Remarks	Officer	250 000 Value: $330.0K
Jan 15, 2025 Buy	Common Stock A-Award	Bressi Jerome Charles See Remarks	Officer	65 000 Value: $85.8K
Jan 15, 2025 Buy	Stock Option (Right to Buy) A-Award	Tahl Cindy See Remarks	Officer	275 000 Value: $363.0K
Jan 15, 2025 Buy	Common Stock A-Award	Tahl Cindy See Remarks	Officer	70 000 Value: $92.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT FATE THERAPEUTICS

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat mul...

Read Full Profile Here